Downstaging and Conversation Strategy for Advanced Hepatocellular Carcinoma with Portal Vein Branch Tumor Thrombus: TACE, ¹²⁵I Seed Implantation, and RFA for Hepatocellular Carcinoma with Portal Vein Branch Tumor Thrombus

References

• Wei X, Jiang Y, Zhang X, et al. Neoadjuvant three-dimensional conformal radiotherapy for resectable hepatocellular carcinoma with portal vein tumor thrombus: a randomized, open-label, multicenter controlled study. J Clin Oncol. 2019;37(24):2141–2151. doi:10.1200/JCO.18.02184
   PubMed Web of Science ®Google Scholar
• Liu PH, Huo TI, Miksad RA. Hepatocellular carcinoma with portal vein tumor involvement: best management strategies. Semin Liver Dis. 2018;38(3):242–251. doi:10.1055/s-0038-1666805
   PubMed Web of Science ®Google Scholar
• Pawarode A, Voravud N, Sriuranpong V, Kullavanijaya P, Patt YZ. Natural history of untreated primary hepatocellular carcinoma: a retrospective study of 157 patients. Am J Clin Oncol. 1998;21(4):386–391. doi:10.1097/00000421-199808000-00014
   PubMed Web of Science ®Google Scholar
• Sun H, Zhang M, Liu R, Liu Y, Hou Y, Wu C. Endovascular implantation of 125I seed combined with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma. Future Oncol. 2018;14(12):1165–1176. doi:10.2217/fon-2017-0354
   PubMed Web of Science ®Google Scholar
• Hu HT, Luo JP, Cao GS, et al. Hepatocellular carcinoma with portal vein tumor thrombus treated with transarterial chemoembolization and Sorafenib vs.125Iodine implantation. Front Oncol. 2021;11:806907. doi:10.3389/fonc.2021.806907
   Web of Science ®Google Scholar
• Sun HC, Zhou J, Wang Z, et al. Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition). Hepatobiliary Surg Nutr. 2022;11(2):227–252. doi:10.21037/hbsn-21-328
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. Electronic address: [email protected]; European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236. doi:10.1016/j.jhep.2018.03.019
   PubMed Web of Science ®Google Scholar
• Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology. 2016;150(4):835–853. doi:10.1053/j.gastro.2015.12.041
   PubMed Web of Science ®Google Scholar
• Shi F, Wu M, Lian SS, et al. Radiofrequency ablation following downstaging of hepatocellular carcinoma by using transarterial chemoembolization: long-term outcomes. Radiology. 2019;293(3):707–715. doi:10.1148/radiol.2019181991
   Web of Science ®Google Scholar
• Zeng ZC, Tang ZY, Fan J, et al. A comparison of chemoembolization combination with and without radiotherapy for unresectable hepatocellular carcinoma. Cancer J. 2004;10(5):307–316. doi:10.1097/00130404-200409000-00008
   PubMed Web of Science ®Google Scholar
• Zhu XD, Huang C, Shen YH, et al. Downstaging and resection of initially unresectable hepatocellular carcinoma with tyrosine kinase inhibitor and Anti-PD-1 antibody combinations. Liver Cancer. 2021;10(4):320–329. doi:10.1159/000514313
   PubMed Web of Science ®Google Scholar
• Lee IJ, Kim JW, Han KH, et al. Concurrent chemoradiotherapy shows long-term survival after conversion from locally advanced to resectable hepatocellular carcinoma. Yonsei Med J. 2014;55(6):1489–1497. doi:10.3349/ymj.2014.55.6.1489
   Web of Science ®Google Scholar
• Yuan H, Cao P, Li HL, et al. Transarterial chemoembolization with radiofrequency ablation versus hepatectomy in hepatocellular carcinoma beyond the Milan criteria: a retrospective study. Cancer Manag Res. 2018;10:5545–5552. doi:10.2147/CMAR.S182914
   PubMed Web of Science ®Google Scholar
• Chen ML, Li HL, Guo CY, et al. Correction to: radiofrequency ablation combined with transarterial chemoembolization in treatment of hepatocellular carcinoma adjacent to the second hepatic hilus. Abdom Radiol. 2022;47(4):1509. doi:10.1007/s00261-022-03424-5
   Web of Science ®Google Scholar
• Huang Y, Zhang Z, Liao W, Hu K, Wang Z. Combination of sorafenib, camrelizumab, transcatheter arterial chemoembolization, and stereotactic body radiation therapy as a novel downstaging strategy in advanced hepatocellular carcinoma with portal vein tumor thrombus: a case series study. Front Oncol. 2021;11:650394. doi:10.3389/fonc.2021.650394
   PubMed Web of Science ®Google Scholar
• Zhang X, Wang K, Wang M, et al. Transarterial chemoembolization (TACE) combined with sorafenib versus TACE for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis. Oncotarget. 2017;8(17):29416–29427. doi:10.18632/oncotarget.15075
   PubMedGoogle Scholar
• Li S, Guo JH, Lu J, et al. I 125 irradiation stent for treatment of hepatocellular carcinoma with portal vein thrombosis: a meta-analysis. Cancer Radiother. 2021;25(4):340–349. doi:10.1016/j.canrad.2020.12.003
   Web of Science ®Google Scholar
• Lucà MG, Nani R, Schranz M, et al. Treatment of hepatocellular carcinoma: a cost analysis of yttrium-90 transarterial radioembolization versus sorafenib. Future Oncol. 2018;14(8):727–735. doi:10.2217/fon-2017-0566
   PubMed Web of Science ®Google Scholar
• Ni JY, Liu SS, Xu LF, Sun HL, Chen YT. Meta-analysis of radiofrequency ablation in combination with transarterial chemoembolization for hepatocellular carcinoma. World J Gastroenterol. 2013;19(24):3872–3882. doi:10.3748/wjg.v19.i24.3872
   PubMed Web of Science ®Google Scholar
• Liu W, Xu H, Ying X, et al. Radiofrequency Ablation (RFA) combined with Transcatheter Arterial Chemoembolization (TACE) for patients with medium-to-large hepatocellular carcinoma: a retrospective analysis of long-term outcome. Med Sci Monit. 2020;26:e923263. doi:10.12659/MSM.923263
   PubMed Web of Science ®Google Scholar
• Dhir M, Sasson AR. Surgical management of liver metastases from colorectal cancer. J Oncol Pract. 2016;12(1):33–39. doi:10.1200/JOP.2015.009
   PubMed Web of Science ®Google Scholar
• Huang SL, Wang YM, Wang QY, et al. Mechanisms and Clinical Trials of Hepatocellular Carcinoma Immunotherapy. Front Genet. 2021;12:691391. doi:10.3389/fgene
   Web of Science ®Google Scholar
• Finn RS, Qin S, Ikeda M, et al. IMbrave150 investigators. atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894–1905. doi:10.1056/NEJMoa1915745
   PubMed Web of Science ®Google Scholar